Advanced searches left 3/3

Car T Cell Therapy - DOAJ

Summarized by Plex Scholar
Last Updated: 10 January 2023

* If you want to update the article please login/register

CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer Patients

For the first time successfully treated with chimeric antigen receptor -modified T cells to target CD19 overexpression in tumor cells, a chronic lymphocytic leukemia patient was seen for the first time in an established lymphocytic leukemia patient was treated with chimeric antigen receptor -modified T cells seven years ago. This was the start of the development of a new form of immunotherapy therapy in cancer patients. However, studies are still struggling to identify issues related to the therapy, such as toxicities associated with the drug's use, and how to prevent tumor cell immune escape mechanisms. The heterogeneity of solid tumors has contributed to the development of novel and experimental CAR-T cell function, in contrast to hematological malignancies. Here, we will review the main clinical findings obtained with CAR-T cells in hematological malignancies, specifically targeting CAR-T-19 and CAR-T against the B-cell maturation antigen. In addition, we will address the main issues that reduce CAR-T cell proliferation in solid tumors and the steps to combat them.

Source link: https://doi.org/10.4274/tjh.2018.0196


Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results

Abstract B-cell maturation antigen-targeting T-cell differentiation antigen has a lot of promise in autoimmune diseases and may be novel therapies for relapsed/refractory neuromyelitis optica spectrum disorder (TS-B3). In all patients with only events of grade 1 or 2 observed, only symptoms of grade 1 or 2 were found, with no complications identified. 11 patients had no relapse; all patients reported improvements in disabilities and quality-of-life; 11 patients' u2019 AQP-4 antibodies in serum showed a downward trend by the cutoff date; 11 patients did not relapse during the follow-up of a median 5. 5 months. In summary, CAR T-cell therapy delivers a safe safety profile and therapeutic potentials for patients with relapsed/refractory AQP4-IgG seropositive NMOSD. Patients with other neuro-inflammatory diseases have a second expansion phase to determine the safety and effectiveness of CAR T-BCMA infusion in patients with other neuro-inflammatory diseases.

Source link: https://doi.org/10.1038/s41392-022-01278-3


Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report

Cardiac involvement in hematological malignancies is unusual, with only a handful cases reported to date, and it often leads to a poor prognosis. We report a case of a 42-year-old woman with a history of allogeneic stem cell transplantation and anti-CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoblastic leukemia in which cardiac mass and myocardial infiltration were noted. In both pericardial effusion and serum, we observed elevated cytokine levels and increased copy number of CAR DNA.

Source link: https://doi.org/10.3389/fimmu.2022.1052336


Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?

Highly resistant B cell malignancies are now treated with Chimeric antigen receptor T cell therapy. CD19 CAR T cells used in the treatment of relapsed and/or refractory non-Hodgkin lymphoma have shown dramatic improvement in survival and response rates. This report will determine whether the findings from these clinical trials are representative of real-world applications by the review of published literature on the commercially available CAR T cell products.

Source link: https://doi.org/10.36401/JIPO-21-2


Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

Abstract Background: aims to find semi-quantitative and quantitative Positron Emission Tomography/Magnetic Resonance imaging results of both tumor and non-malignant lymphoma tissue in patients with progression Free Survival and Overall Survival in patients with chronic large B-cell lymphoma treatment with Chimeric Antigen Receptor T-cell therapy. Methods A single-center prospective study of 16 r/r LBCL patients undergoing CD19-targeted CAR T-cell therapy found no results. Maximum Standardized Uptake Value, mean SUV, Metabolic Tumor Volume, Tumor Lesion Glycolysis, total tumor burden, and mean Apparent Diffusion Coefficient were among Tumor metrics reported on Tumor metrics. The association between extracted metrics and PFS and OS was determined by univariate Cox regression study. PPS is a determinant that bone marrow SUVmean was correlated with PFS p 0. 05. Conclusions MTV, tumor ADCmean, and FDG uptake in bone marrow that have been unaffected by tumor infiltration are potential PET/MR metrics for prediction of PFS and OS in r/r LBCL treated with CAR T-cells.

Source link: https://doi.org/10.1186/s40644-022-00513-y


Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center.

Patients' highly personalized immunotherapy require real world safety, toxicity, and cost analyses from chimeric antigen receptor -T cell therapy, of utmost importance in determining whether and how to provide patients with personalized immunotherapy. In this research, we aimed to describe CAR T-cells' effectiveness, safety, and cost in a Portuguese Comprehensive Cancer Center. Between May 2019 and February 2021, we conducted a retrospective descriptive review of adult patients with relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and modified follicular lymphoma related to CAR T-cell therapy. When excluding drug cost, CAR T-cell therapy expenditure, which includes adverse events expenses, was 7 176 196, or 286 238 ac. The total cost for the treated patient was 355 165 u20ac, with CAR T-cell drug cost accounting for 97. 0% of the total cost. Our findings reveal the significant economic burden of CAR T-cell therapy exacerbated by medication acquisition costs, as shown by our results.

Source link: https://doi.org/10.1371/journal.pone.0278950


Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis

BackgroundCD22 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy are among promising immunotherapy approaches for the treatment of hematologic malignancies. B-cell lymphoblastic leukemia, relapsed or refractory B-cell lymphoblastic leukemia were 0. 75 to 0. 87 compared to CAR-T cell therapy for relapsed or refractory B-cell lymphoblastic leukemia. The overall MRD negative response rates of CD22 and CD19/CD22 CAR-T were 0. 54 and 0. 91, respectively. Both pooled CRS and CD19/CD22 targeted immunotherapy were 0. 92 and 0. 94 respectively, respectively. ConclusionBoth CD22 and CD19/CD22 CAR-T immunotherapy in the treatment of hematologic malignancies were demonstrated with positive safety and acceptable adverse events.

Source link: https://doi.org/10.3389/fonc.2022.954345


The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma

Patients with relapsed/refractory large B-cell lymphoma following frontline therapy have been treated to autologous hematopoietic cell transplantation for over three decades. Acute DLBCL was first approved for relapsed DLBCL after two or more previous lines of therapy with long-lasting effects, with over half of patients still alive at 5-year follow-up.

Source link: https://doi.org/10.1177/20406207221141511


Radiotherapy plus CAR-T cell therapy to date: A note for cautions optimism?

Factors such as hypoxia, the radiosensitivity of immune cells, and cancer stem cells all factor in determining the determining effect of radioresistance in the irradiated tumor microenvironment. In addition, CAR-T cells targeting CSC-related genes would prevent radioresistant solid tumors from emerging. But solid tumors that support an immune deserted TME are described as immunosuppressive and do not respond to CAR-T cell therapy. And RT could mask these immunosuppressive characteristics; therefore, increasing evidence supports the combination of RT and CAR-T cell therapy.

Source link: https://doi.org/10.3389/fimmu.2022.1033512


Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

Multiple myeloma patients treated with anti-CD19 CAR T for lymphoma and 47 patients treated with anti-BCMA CAR T for multiple myeloma were retrospectively reviewed to determine the effects of G-CSF. Before CAR T, 140 patients were given prophylactic G-CSF before CAR T, and compared with 57 patients treated with G-CSF after CAR T was determined or not revealed. Patients were stratified by early G-CSF use, with no significant difference in toxicities in multiple myeloma patients; prophylactic G-CSF was not used in multiple myeloma cases; patients were stratified by early G-CSF in multiple myeloma; no difference was found in toxicities.

Source link: https://doi.org/10.1038/s41408-022-00741-2

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions